Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00116610
Status:
COMPLETED
Last Update Posted:
2009-01-21
First Post:
2005-06-29
Brief Title:
Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer
Sponsor:
Poniard Pharmaceuticals
Organization:
Poniard Pharmaceuticals
Study Overview
Official Title:
A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II research study that is designed for patients who have small cell lung cancer SCLC that is no longer responding to treatment Patients will receive picoplatin a new platinum-based agent that is currently under investigation in 21-day cycles
Detailed Description:
Platinum drugs work by binding to DNA and preventing the rapid cell division of tumors However many tumors demonstrate a resistance to platinum drugs Results from preclinical studies indicate that picoplatin previously called AMD473 or ZD0473 may be able to overcome or partially overcome platinum resistance More than 500 patients have received picoplatin in previous Phase I or Phase II clinical trials
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IND No 69507 | None | None | None |